Lornoxicam-BP

Lornoxicam

One vial contains the active substance lornoxicam 8 mg.

Indication: Short-term relief of mild to moderate acute pain in adults.

Contraindications (SmPC sec. 4.3): 4.3 Contraindications - Hypersensitivity to lornoxicam or to any of the excipients listed in section 6.1. - Thrombocytopenia. - Hypersensitivity (manifestations such as bronchial asthma, rhinitis, angioedema or urticaria) to other NSAIDs, including acetylsalicylic acid. - Severe heart failure. - Gastrointestinal haemorrhage, cerebrovascular haemorrhage or other bleeding disorders. - History of gastrointestinal bleeding or perforation associated with previous NSAID therapy. - Active peptic ulcer/haemorrhage or a history of recurrent peptic ulcer/haemorrhage (two or more distinct episodes of ulceration or bleeding). - Severe hepatic impairment. - Severe renal impairment (serum creatinine > 700 μmol/l). - Third trimester of pregnancy (see section 4.6).

Special warnings and precautions (SmPC sec. 4.4, excerpt): 4.4 Special warnings and precautions for use Lornoxicam should be given only after careful assessment of the risk-benefit ratio in patients with: − Renal impairment: lornoxicam should be given with caution in patients with mild (serum creatinine 150-300 μmol/l) to moderate (serum creatinine 300-700 μmol/l) renal impairment, as maintenance of renal blood flow is prostaglandin-dependent (see section 4.2). Treatment with lornoxicam should be discontinued if renal function deteriorates during treatment. Renal function should be monitored in patients: - undergoing major surgery, - with heart failure, - concomitantly treated with diuretics or medicinal products presumed or known to cause renal impairment (see section 4.5). - with blood coagulation disorders: it is recommended […]